Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine

BIOLOGICAL9 trials

Sponsors

Merck Sharp & Dohme LLC, AIDS Malignancy Consortium, National Cancer Institute (NCI)

Conditions

Anal CancerCervical CancerHPV InfectionsHealthy Adult Female ParticipantsHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Human Papillomavirus-Related Cervical CarcinomaNonneoplastic ConditionPapillomavirus Infection

Phase 1

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

CompletedNCT00635830

Merck Sharp & Dohme LLCHPV Infections

Start: 2008-03-31End: 2008-04-30Updated: 2015-10-09

Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

CompletedNCT00667563

AIDS Malignancy ConsortiumCervical Cancer, Nonneoplastic Condition, Precancerous Condition

Start: 2009-08-31End: 2012-11-30Updated: 2024-03-19

Phase 2

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

CompletedNCT00378560

Merck Sharp & Dohme LLCHPV Infections

Start: 2006-06-12End: 2009-09-16Updated: 2017-04-17

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

CompletedNCT01209325

AIDS Malignancy ConsortiumAnal Cancer, Nonneoplastic Condition, Penile Cancer +1

Start: 2011-06-28End: 2017-12-12Updated: 2020-08-11

Phase 3

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

CompletedNCT00090220

Merck Sharp & Dohme LLCHealthy Adult Female Participants, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Papillomavirus Infection +1

Start: 2004-06-16End: 2015-11-12Updated: 2017-04-21

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

CompletedNCT00380367

Merck Sharp & Dohme LLCPapillomavirus Infections

Start: 2007-05-03End: 2008-02-04Updated: 2023-05-31

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

WithdrawnNCT00733122

Merck Sharp & Dohme LLCHPV Infections

Start: 2009-10-01End: 2013-10-01Updated: 2025-03-03

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

CompletedNCT00834106

Merck Sharp & Dohme LLCHPV Infections

Start: 2008-12-31End: 2016-09-30Updated: 2019-02-04

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

CompletedNCT03728881

National Cancer Institute (NCI)Human Papillomavirus-Related Cervical Carcinoma

Start: 2019-04-01End: 2024-04-23Updated: 2025-08-03

Related Papers

Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9-14 years compared with three doses of quadrivalent HPV vaccine in women aged 18-25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial.

2025-07-16

The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20–45 years of age

Human Vaccines & Immunotherapeutics2024-10-111 citations

[Evaluation of the 10-year protective effect and immunogenicity of quadrivalent HPV vaccination].

PubMed2024-10-06

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants

Human Vaccines & Immunotherapeutics2022-08-232 citations

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years

Human Vaccines & Immunotherapeutics2022-07-1930 citations

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age

Human Vaccines & Immunotherapeutics2022-03-3118 citations

Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants

Papillomavirus Research2020-08-195 citations

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology

BMJ evidence-based medicine2020-03-179 citations

Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men.

2019-01-1524 citations

Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.

2019-01-0927 citations

Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.

2018-08-1646 citations

Association between pap abnormalities and HPV infection in participants in HPV vaccine clinical trials.

Journal of Clinical Oncology2018-05-20

Results disclosure of papilloma vaccine studies in humans completed before January 1st, 2011.

Figshare2014-01-01

Results disclosure of papilloma vaccine studies in humans co.

Figshare2014-01-01

Long-Term Follow-up Observation of the Safety, Immunogenicity, and Effectiveness of Gardasil™ in Adult Women

PLoS ONE2013-12-3181 citations

Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine.

2012-04-1816 citations

Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.

2009-12-0179 citations

Prevalence and incidence of HPV genital infection in women.

2009-11-0137 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

2009-06-01317 citations